Literature DB >> 16637266

[Association of polymorphisms in SULT1A1 and UGT1A1 Genes with breast cancer risk and phenotypes in Russian women].

E G Shatalova, V I Loginov, E A Braga, T P Kazubskaia, M A Sudomoina, R L Blanchard, O O Favorova.   

Abstract

Estrogens are critical for breast cancer initiation and development. Sulfotransferase 1A1 (SULT1A1) and UDP-glucuronosyltransferase 1A1 (UGT1A1) conjugate and inactivate both estrogens and their metabolites, thus preventing estrogen-mediated mitosis and mutagenesis. SULT1A1 and UGT1A1 genes are both polymorphic, and different alleles encode functionally different allozymes. We hypothesize that low activity alleles SULT1A1*2 and UGT1A1*28 are associated with the higher risk for breast cancer and more severe breast tumor phenotypes. We performed a case-control study, which included 119 women of Russian ancestry with breast cancer and 121 age-matched Russian female controls. We used PCR, followed by pyrosequencing to determine SULT1A1 and UGT1A1 genotypes. Our data showed that UGT1A1*28 allele was presented at a higher frequency than the wild type UGT1A1*1 allele in breast cancer patients as compared to controls (p = 0.002, OR = 1.79, CI 1.23-2.63). Consistently, the frequency of genotypes that contain the UGT1A1*28 allele in the homozygous or heterozygous state was greater than the frequency of the wild type UGT1A1*1/*1 genotype in breast cancer patients as compared to controls (p = 0.003, OR = 4.00, CI 1.49-11.11 and p = 0.014, OR = 2.04, CI 1.14-3.57, respectively). The group of individuals, carrying the UGT1A1*28 allele in the homo- or heterozygous state also presented larger breast tumors (>2 cm) as compared to the group with high enzymatic activity genotypes p = 0.011, OR = 3.44, CI 1.42-8.36). No association was observed between any of the SULT1A1 genotypes and breast cancer risk or phenotypes. Our data suggest that UGT1A1 but not SULT1A1 genotype might be important for breast cancer risk and phenotype in Russian women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16637266

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  7 in total

Review 1.  Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

Authors:  Celia N Sanchez-Dominguez; Hugo L Gallardo-Blanco; Mauricio A Salinas-Santander; Rocio Ortiz-Lopez
Journal:  Exp Ther Med       Date:  2018-05-18       Impact factor: 2.447

2.  Prevalence of the UGT1A1*28 promoter polymorphism and breast cancer risk among African American women in Memphis, TN.

Authors:  Alana Smith; Cheryl D Cropp; Gregory Vidal; Elizabeth Pritchard; Jennifer Cordero; Claire Simpson; Athena Starlard-Davenport
Journal:  Cancer Health Disparities       Date:  2019-08-19

3.  Gilbert's Syndrome, Bilirubin Level and UGT1A1∗28 Genotype in Men of North-West Region of Russia.

Authors:  Andrei Ivanov; Elena Semenova
Journal:  J Clin Exp Hepatol       Date:  2021-02-04

4.  Bisphenol-A glucuronidation in human liver and breast: identification of UDP-glucuronosyltransferases (UGTs) and influence of genetic polymorphisms.

Authors:  Christina M Street; Zhaohui Zhu; Moshe Finel; Michael H Court
Journal:  Xenobiotica       Date:  2016-03-21       Impact factor: 1.908

5.  Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics.

Authors:  Jurij Trontelj; Janja Marc; Andrej Zavratnik; Marija Bogataj; Ales Mrhar
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

6.  Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans.

Authors:  Dezheng Huo; Hee-Jin Kim; Clement A Adebamowo; Temidayo O Ogundiran; Effiong E Akang; Oladapo Campbell; Adeniyi Adenipekun; Qun Niu; Lise Sveen; James D Fackenthal; Donna Lee Fackenthal; Soma Das; Nancy Cox; Anna Di Rienzo; Olufunmilayo I Olopade
Journal:  Breast Cancer Res Treat       Date:  2007-10-02       Impact factor: 4.872

7.  Investigation of prognostic value of polymorphisms within estrogen metabolizing genes in Lithuanian breast cancer patients.

Authors:  Aistė Savukaitytė; Rasa Ugenskienė; Roberta Jankauskaitė; Darius Čereškevičius; Eglė Šepetauskienė; Elona Juozaitytė
Journal:  BMC Med Genet       Date:  2015-02-04       Impact factor: 2.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.